A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).
There are two stages in this study: Stage 1 will have two treatment arms and one control arm, and Stage 2 will have a treatment arm and a control arm. The control arms in Stages 1 and 2 are the same.
Each stage of the study consists of a screening period (up to 21 days), an induction period followed by a maintenance period (until confirmed disease progression, intolerable toxicity, participant withdrawal, study termination or up to 2 years [whichever occurs first]), and a follow-up (FU) period for all participants (2 safety FU visits and survival FU visits).
In Stage 1, eligible participants will be randomized (1:1:1) to the arms. In Stage 2, participants will then be randomized (1:1) to the arms. The randomization will be stratified based on the following factors:
Participants will be allowed to switch to cisplatin if carboplatin is not tolerated at the investigator's discretion.
Inclusion Criteria:
Exclusion Criteria:
Have histologically or cytologically confirmed SCLC with combined histologies.
Have received any of the following therapies or drugs within the noted time intervals prior to study treatment:
Have the following central nervous system metastases:
Have uncontrolled hypertension or poorly controlled diabetes prior to study treatment.
Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess for which an interval of 6 months must pass before study entry. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation.
Have a significant risk of hemorrhage (per investigator clinical judgment) as defined in the protocol.
Have superior vena cava syndrome or symptoms of spinal cord compression that requires urgent medical intervention.
NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
patients@biontech.de+49 6131 9084 ext. 0
Frederick, Maryland 21704, United States
Burlington, Massachusetts 01805, United States
New York, New York 10065, United States
Cleveland, Ohio 44111, United States
Fountain Hill, Pennsylvania 18015-1153, United States
Fredericksburg, Virginia 22408, United States
Richmond, Virginia 23298, United States
Frankston, Victoria 3199, Australia
Taiyuan, 030013, China
Wuhan, 430022, China
Xinxiang, 453100, China
Zhengzhou, 450008, China
Bordeaux, 33076, France
Saint-Herblain, 44805, France
Toulon, 83056, France
Berlin, 13353, Germany
Meldola, 47014, Italy
Monza, 20900, Italy
Osaka, 541-8567, Japan
Bucharest, 022328, Romania
Craiova, 200542, Romania
Suwon, Gyeonggi-do 16247, South Korea
Valencia, 46026, Spain
Adana, 1250, Turkey (Türkiye)
Ankara, 6200, Turkey (Türkiye)
Chelsea, London SW3 6JJ, United Kingdom
Sutton, London SM2 5PT, United Kingdom
Huddersfield, North Yorkshire HD3 3EA, United Kingdom
Newcastle upon Tyne, Northumberland NE7 7DN, United Kingdom
Nottingham, Nottinghamshire NG5 1PB, United Kingdom
Oxford, Oxfordshire OX3 7LE, United Kingdom
Dundee, Scotland DD1 9SY, United Kingdom
Stoke-on-Trent, Staffordshire ST4 6QG, United Kingdom
Cambridge, CB2 0QQ, United Kingdom
Exeter, EX2 5DW, United Kingdom
Leeds, LS9 7TF, United Kingdom